Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111832 | 0.87 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1ADORA2AADORA2BADORA1 | |
| SCHEMBL13080598 | 0.87 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1ADORA2AADORA2BADORA1 | |
| SCHEMBL13520073 | 0.86 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1ADORA2AADORA2BADORA1 | |
| SCHEMBL3515942 | 0.86 | ADORA2A (0.56) | HSP90AA1HSP90AB1ADORA2AADORA2BADORA1 | |
| SCHEMBL27774220 | 0.84 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1ADORA2AADORA2BADORA1 | |
| SCHEMBL14384958 | 0.83 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 | |
| SCHEMBL3751306 | 0.82 | PI4KA (0.50) | ADORA2AADORA2BADORA1 | |
| SCHEMBL3517750 | 0.82 | ADORA2A (0.59) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL3119789 | 0.81 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1ADORA2AADORA2BADORA1 | |
| SCHEMBL3119774 | 0.81 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | claimed |
| US-20130053406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MYREXIS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MYREXIS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | VHL, TP53, MCL1 | HSP90AA1 815/4885HSP90AB1 423/4885ADORA2A 2643/4885 |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | HSP90AA1 659/4885HSP90AB1 501/4885ADORA2A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.